Danaher Life Sciences — Intangible Amortization decreased by 1.9% to $151.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.0%, from $148.00M to $151.00M. Over 3 years (FY 2022 to FY 2025), Life Sciences — Intangible Amortization shows an upward trend with a 13.0% CAGR.
High amortization often reflects a history of aggressive acquisition activity and significant investment in intellectual property.
The periodic expense recognized for the consumption of intangible assets, such as patents, trademarks, and acquired tech...
Common in M&A-heavy industries; peers with similar acquisition strategies will report significant amortization.
dhr_segment_life_sciences_amortization_of_intangible_assets| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.75M | $104.75M | $104.75M | $104.75M | $107.25M | $107.25M | $107.25M | $107.25M | $141.00M | $140.00M | $147.00M | $148.00M | $149.00M | $150.00M | $154.00M | $151.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +2.4% | +0.0% | +0.0% | +0.0% | +31.5% | -0.7% | +5.0% | +0.7% | +0.7% | +0.7% | +2.7% | -1.9% |
| YoY Change | — | — | — | — | +2.4% | +2.4% | +2.4% | +2.4% | +31.5% | +30.5% | +37.1% | +38.0% | +5.7% | +7.1% | +4.8% | +2.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.